<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-C
Report by Issuer of Securities Quoted on NASDAQ
Interdealer Quotation System
Filed pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 and Rule 13a-17
or 15d-17 thereunder
NORTH AMERICAN BIOLOGICALS, INC.
(Exact name of issuer as specified in charter)
5800 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487
(Address of principal executive offices)
Issuer's telephone number, including area code: (407) 989-5800
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number
of shares outstanding:
1. Title of security: Common Stock, par value $.10 per share.
2. Number of shares outstanding before the change: 14,957,559.
3. Number of shares outstanding after the change: 10,469,079.
4. Effective date of change: March 31, 1992.
5. Method of change: Repurchase of outstanding shares and issuance
of additional shares.
Brief description of transaction: On March 31, 1992, the issuer
repurchased 6,180,786 shares of Common Stock from Continental Pharma Cryosan
Inc. and its affiliates and, in connection with the transaction, issued
1,692,306 shares of Common Stock in a private placement.
Date: November 13, 1995 /s/ Alfred J. Fernandez
-----------------------------
(Officer's signature)
Vice President Finance and
Chief Financial Officer
------------------------------
(Officer's title)